PMID- 20719187
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20121002
LR  - 20100819
IS  - 1999-6187 (Electronic)
IS  - 1009-3419 (Linking)
VI  - 12
IP  - 8
DP  - 2009 Aug 20
TI  - [Selection of Therapy Method for Stage III Non Small Cell Lung Cancer after 
      Induction Chemotherapy.].
PG  - 939-42
LID - 10.3779/j.issn.1009-3419.2009.08.23 [doi]
AB  - BACKGROUND: It is the main choice that neoadjust chemotherapy following surgery 
      and induction chemotherapy following radiation therapy for locally advanced lung 
      cancer. The aim of this study is to explore the selection of operation or 
      synchronous radiotherapy and chemotherapy for stage III non small cell lung 
      cancer (NSCLC) after induction chemotherapy. METHODS: After two cycles of 
      induction chemotherapy, patients with stage III NSCLC were divided at random into 
      synchronous radiotherapy and chemotherapy group or operation therapy group for 
      therapy by the chemotherapy effect PR or CR, or estimated complete excision; and 
      patients accepting complete excision operation continuously accepted two cycles 
      of chemotherapy according to original proposal. RESULTS: Total 71 patients with 
      stage III NSCLC entered therapy group after induction chemotherapy. Where, 37 
      patients accepted synchronous radiotherapy and chemotherapy, and 34 patients 
      accepted operation. The 1-year, 2-year, and 3-year survival rate of synchronous 
      radiotherapy and chemotherapy group was 78.4%, 40.5% and 23.4% respectively, 
      while that of operation group was 81.1%, 39.5% and 35.1% respectively. The medium 
      survival of the two groups was 18.0+/-2.4 and 23.0+/-1.6 respectively, and there 
      was no statistical difference (P=0.23) in survival rate. The disease-free 
      survival rate of synchronous radiotherapy and chemotherapy group and operation 
      group was 14.0+/-1.7 months and 19.0+/-3.2 months respectively (P=0.044), and 
      obviously, there was statistical difference. CONCLUSIONS: After induction 
      chemotherapy, patients with stage III NSCLC could select operation therapy and 
      synchronous radiotherapy and chemotherapy. Where, synchronous radiotherapy and 
      chemotherapy is relatively safe, but the adverse reaction can't be ignored. 
      Operation therapy has higher risk and difficulty for induction chemotherapy, but 
      has shown its superiority in disease-free survival.
FAU - Hu, Zhendong
AU  - Hu Z
AD  - Department of Thoracic Surgery,Jiangsu Cancer Hospital, Nanjing 210009, China.
FAU - Lu, Jianwei
AU  - Lu J
FAU - Zhu, Jun
AU  - Zhu J
FAU - Zhu, Liangjun
AU  - Zhu L
FAU - Xu, Lin
AU  - Xu L
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhongguo Fei Ai Za Zhi
JT  - Zhongguo fei ai za zhi = Chinese journal of lung cancer
JID - 101126433
EDAT- 2010/08/20 06:00
MHDA- 2010/08/20 06:01
CRDT- 2010/08/20 06:00
PHST- 2010/08/20 06:00 [entrez]
PHST- 2010/08/20 06:00 [pubmed]
PHST- 2010/08/20 06:01 [medline]
AID - 10.3779/j.issn.1009-3419.2009.08.23 [doi]
PST - ppublish
SO  - Zhongguo Fei Ai Za Zhi. 2009 Aug 20;12(8):939-42. doi: 
      10.3779/j.issn.1009-3419.2009.08.23.